Invasive Malignant Neoplasm — Trials

Invasive Malignant Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

1,820 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 604
Recruiting: 302
Ph III recruiting: 36
Growth YoY: +27.2%
Industry share: 19%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (283)

clinicaltrialsPublishedShowing 151–200 of 688 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07480356	Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer(ADVANCED-3)	recruiting	Phase 3	284	Protara TherapeuticsINDUSTRY	2	Aug 21, 2026	clinicaltrials
NCT04673448	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	Phase 1	18	University of WashingtonOTHER